News Alpha Tau Medical Ltd.

Equities

DRTS

IL0011839383

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-15 EDT			5-day change	1st Jan Change
2.65 ^USD	+0.61%		+9.96%	-11.96%

05-06	Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow	CI
03-07	Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer	05-13	GL
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer	05-13	AQ
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow	05-06	AQ
Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow	05-06	CI
Alpha Tau to Participate in May Investor Conferences	05-01	AQ
Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit	03-25	AQ
Alpha Tau Medical : to Present at the Jefferies Radiopharma Innovation Summit - Form 6-K	03-25	PU
Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update	03-07	AQ
Alpha Tau Medical Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
Alpha Tau Medical : Corporate Presentation – March 2024	03-03	PU
Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference	02-26	AQ
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference	12-20	GL
Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference	12-20	AQ
Alpha Tau to Participate in Sidoti Small-Cap Conference	11-29	AQ
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer	11-28	GL
Alpha Tau Medical Ltd. Announces Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer	11-28	CI
Alpha Tau, HekaBio Seek Japan's Premarket Approval of Alpha-Radiation Therapy for Head, Neck Cancer	11-20	MT
Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer	11-20	GL
Alpha Tau Medical Ltd. Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer	11-20	CI
Piper Sandler Adjusts Alpha Tau Medical's Price Target to $8 From $12, Keeps Overweight Rating	11-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Alpha Tau Medical Ltd.

Equities

DRTS

IL0011839383

Summary

Filters